Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.

Toyoda, Hidenori ORCID: 0000-0002-1652-6168, Kanneganti, Mounika, Melendez-Torres, Jonathan, Parikh, Neehar D ORCID: 0000-0002-5874-9933, Jalal, Prasun K ORCID: 0000-0001-5353-2324, Piñero, Federico, Mendizabal, Manuel, Ridruejo, Ezequiel, Cheinquer, Hugo, Casadei-Gardini, Andrea ORCID: 0000-0001-6289-7202
et al (show 27 more authors) (2024) Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 22 (1). 72-80.e4.

[img] Text
CGH.pdf - Author Accepted Manuscript
Available under License Creative Commons Attribution.

Download (1MB) | Preview


<h4>Background & aims</h4>Widespread use of direct-acting antivirals for hepatitis C virus infection has been paralleled with increased numbers of patients with hepatocellular carcinoma (HCC) after achieving sustained virologic response (post-SVR HCC) worldwide. Few data compare regional differences in the presentation and prognosis of patients with post-SVR HCC.<h4>Methods</h4>We identified patients with advanced fibrosis (F3/F4) who developed incident post-SVR HCC between March 2015 and October 2021 from 30 sites in Europe, North America, South America, the Middle East, South Asia, East Asia, and Southeast Asia. We compared patient demographics, liver dysfunction, and tumor burden by region. We compared overall survival by region using Kaplan-Meier analysis and identified factors associated with survival using multivariable Cox regression analysis.<h4>Results</h4>Among 8796 patients with advanced fibrosis or cirrhosis who achieved SVR, 583 (6.6%) developed incident HCC. There was marked regional variation in the proportion of patients detected by surveillance (range: 59.5%-100%), median maximum tumor diameter (range, 1.8-5.0 cm), and the proportion with multinodular HCC (range, 15.4%-60.8%). The prognosis of patients highly varied by region (hazard ratio range, 1.82-9.92), with the highest survival rates in East Asia, North America, and South America, and the lowest survival rates in the Middle East and South Asia. After adjusting for geographic region, HCC surveillance was associated with early stage detection (Barcelona Clinic Liver Cancer stage 0/A, 71.0% vs 21.3%; P < .0001) and lower mortality rates (adjusted hazard ratio, 0.29; 95% CI, 0.18-0.46).<h4>Conclusions</h4>Clinical characteristics, including early stage detection, and prognosis of post-SVR HCC differed significantly across geographic regions. Surveillance utilization appears to be a high-yield intervention target to improve prognosis among patients with post-SVR HCC globally.

Item Type: Article
Uncontrolled Keywords: Humans, Hepacivirus, Hepatitis C, Chronic, Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis, Antiviral Agents, Prognosis, Risk Factors, Sustained Virologic Response
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 07 Aug 2023 12:59
Last Modified: 13 Jan 2024 02:07
DOI: 10.1016/j.cgh.2023.06.026
Related URLs: